Inspire Medical Systems, Inc.

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Net income (loss) ($17.5m) ($21.8m) ($33.2m) ($57.2m) ($42.0m) ($44.9m) ($21.2m) $53.5m $145.4m
Depreciation and amortization $285k $393k $495k $840k $1.2m $1.9m $2.8m $6.5m $14.0m
Deferred income taxes (benefit) $0 $0 ($88.7m)
Impairment of strategic investment $0 $0 $4.0m
Accretion of investment discount $0 ($648k) ($983k) ($22k) $14k ($4k) ($2.5m) ($8.9m) ($2.9m)
Stock-based compensation expense $243k $1.2m $6.2m $12.8m $26.2m $52.0m $82.5m $116.0m $130.3m
Provision (benefit) for estimated credit losses ($63k) $1.6m ($768k) $200k
Other non-cash expenses $879k $2.1m $1.5m $2.1m
Accounts receivable ($1.8m) ($2.8m) ($6.5m) ($11.8m) ($9.2m) ($27.0m) ($30.2m) ($2.6m) ($26.2m)
Inventories ($315k) $1.0m ($3.2m) ($2.6m) ($8.8m) $5.3m ($22.0m) ($46.2m) ($65.2m)
Prepaid expenses and other current assets ($308k) ($1.3m) ($905k) $416k ($696k) ($2.8m) ($4.8m) ($2.3m) $1.7m
Accounts payable $1.8m $439k $1.0m $2.0m $4.8m $14.4m $9.3m $604k ($3.7m)
Accrued expenses and other liabilities $1.3m $3.6m $2.9m $1.1m $7.1m $11.9m $6.9m $12.9m $6.1m
Purchases of property and equipment ($412k) ($250k) ($2.7m) ($2.5m) ($4.7m) ($9.1m) ($23.6m) ($39.1m) ($38.5m)
Proceeds from the exercise of stock options $235k $558k $1.1m $7.0m $11.5m $12.1m $25.8m $22.2m $9.6m
Payment of taxes on net share settlement of equity awards $0 $0 ($43k) ($17.2m) ($5.2m) ($23.0m)
Property and equipment included in accounts payable and accrued expenses $0 $0 $816k $274k $2.1m $4.0m $3.4m $4.8m
Excise taxes accrued but not paid $0 $0 $1.0m
Net cash provided by operating activities ($15.8m) ($18.7m) ($32.8m) ($53.0m) ($20.1m) $11.6m $24.7m $130.2m $117.0m
Purchases of investments ($9.0m) ($115.5m) ($178.1m) ($52.7m) ($10.0m) $0 ($281.2m) ($418.4m) ($240.3m)
Purchases of strategic investments $0 $0 ($10.5m) ($250k) ($250k) ($10.1m)
Proceeds from sales or maturities of investments $1.8m $32.3m $137.3m $141.8m $43.8m $0 $10.2m $344.6m $310.4m
Net cash provided by (used in) investing activities ($7.6m) ($83.4m) ($43.6m) $86.6m $29.1m ($19.6m) ($294.8m) ($113.1m) $21.4m
Proceeds from the issuance of common stock from employee stock purchase plan $0 $0 $1.4m $2.4m $3.5m $3.7m $5.3m $5.6m $5.0m
Accelerated share repurchase of common stock $0 ($75.0m) $0
Share repurchase of common stock $0 $0 ($75.0m) ($175.0m)
Net cash (used in) provided by financing activities $25.7m $190.4m $2.0m $134.1m $14.9m $235.1m $13.9m ($52.4m) ($183.4m)
Effect of exchange rate on cash $0 $33k $13k $11k ($19k) $75k $164k ($118k) ($310k)
Decrease in cash and cash equivalents $2.3m $88.3m ($74.4m) $167.7m $23.9m $227.1m ($256.1m) ($35.4m) ($45.3m)
Cash and cash equivalents at beginning of year $9.0m $97.3m $22.9m $190.5m $214.5m $441.6m $185.5m $150.2m $104.8m
Cash paid for interest $1.3m $2.0m $2.0m $1.9m $1.9m $2.3m $0 $22k $137k